In a reader survey, researchers and core lab staff share how they think cores are doing.
In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings, and more.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Researchers are working on RNA inference-based pesticides for crops, according to Digital Trends.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.